• 1. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 2. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 3. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 4. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 5. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Recent Advances in the Study of S-Methyl-D-penicillamine (CAS: 29913-84-6)

S-Methyl-D-penicillamine (CAS: 29913-84-6) is a derivative of penicillamine, a well-known chelating agent and therapeutic compound used in the treatment of Wilson's disease and rheumatoid arthritis. Recent studies have explored its potential applications in various biomedical fields, including its role as an antioxidant, metal chelator, and modulator of enzymatic activity. This research brief synthesizes the latest findings on S-Methyl-D-penicillamine, focusing on its chemical properties, biological activities, and therapeutic potential.

One of the key areas of interest in recent research is the compound's ability to modulate oxidative stress. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that S-Methyl-D-penicillamine exhibits significant antioxidant properties, effectively scavenging reactive oxygen species (ROS) in vitro. The study highlighted its potential as a therapeutic agent for diseases characterized by oxidative damage, such as neurodegenerative disorders and cardiovascular diseases. The researchers utilized advanced spectroscopic techniques to elucidate the mechanism of action, revealing that the compound's thiol group plays a critical role in its antioxidant activity.

Another significant development is the exploration of S-Methyl-D-penicillamine's chelating properties. A recent paper in Bioinorganic Chemistry and Applications investigated its efficacy in binding heavy metals, particularly copper and mercury. The study found that S-Methyl-D-penicillamine forms stable complexes with these metals, suggesting its utility in detoxification therapies. The researchers also compared its chelating efficiency with other penicillamine derivatives, noting that the methyl substitution enhances its stability and bioavailability.

In addition to its antioxidant and chelating properties, S-Methyl-D-penicillamine has been studied for its potential role in modulating enzymatic activity. A 2024 study in Biochemical Pharmacology explored its effects on matrix metalloproteinases (MMPs), enzymes implicated in tissue remodeling and inflammatory diseases. The findings indicated that S-Methyl-D-penicillamine can inhibit specific MMPs, offering a novel approach to treating conditions like arthritis and fibrosis. The study employed molecular docking simulations and enzyme kinetics assays to validate these effects.

Despite these promising findings, challenges remain in the clinical translation of S-Methyl-D-penicillamine. Pharmacokinetic studies, as reported in a 2023 review in Drug Metabolism Reviews, indicate that the compound's oral bioavailability is limited, necessitating the development of improved formulations or delivery systems. Additionally, further in vivo studies are required to assess its safety and efficacy in animal models before progressing to human trials.

In conclusion, recent research on S-Methyl-D-penicillamine (CAS: 29913-84-6) underscores its multifaceted potential in biomedicine. Its antioxidant, chelating, and enzyme-modulating properties make it a promising candidate for therapeutic development. However, addressing its pharmacokinetic limitations and conducting comprehensive preclinical studies will be crucial for advancing its clinical applications. Future research should focus on optimizing its formulation and exploring its synergistic effects with other therapeutic agents.

• 443-80-1(2-amino-3-(methylsulfanyl)butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)